My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

38.81 +1.47 (+3.94%)

Streaming Delayed Price Updated: 9:54 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cogent Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M ↗

February 01, 2026

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge ↗

January 11, 2026

Focused on precision therapies for rare diseases, this biotech firm reported a significant insider sale amid a year of sharp share gains.

Via The Motley Fool

Topics Regulatory Compliance

What's going on in today's after hours session ↗

December 30, 2025

Via Chartmill

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗

November 10, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Top movers in Monday's session ↗

November 10, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 10, 2025

Via Benzinga

Gold Jumps Over 2%; Dole Shares Gain After Q3 Results ↗

November 10, 2025

Via Benzinga

Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise ↗

November 10, 2025

The company is working to improve outcomes for patients with gastrointestinal stromal tumors, or GIST.

Via Investor's Business Daily

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 10, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial ↗

November 10, 2025

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.

Via Benzinga

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗

November 10, 2025

Via Benzinga

S&P 500 Surges 1%; Tyson Foods Posts Upbeat Earnings ↗

November 10, 2025

Via Benzinga

Topics Stocks

Monday's pre-market session: top gainers and losers ↗

November 10, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results

October 13, 2025

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from...

Via MarketMinute

Topics Economy Supply Chain

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags ↗

July 21, 2025

According to the technical analysis of over 4,400 firms with a market cap exceeding $100 million, three firms are in the overbought zone.

Via Benzinga

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges ↗

July 08, 2025

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Via Stocktwits

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.